Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2 million; G&A down 48%

Mixed Impact 3 of 5 earnings Written later

Calidi Biotherapeutics reported a second-quarter 2026 net loss attributable to common stockholders of $4.2 million, or $2.94 per share, compared with $5.7 million, or $31.75 per share, a year earlier; per-share figures reflect a 1-for-16 reverse split completed in July 2026. Cash fell to $4.1 million by June 30, 2026, and the company's filing lists the risk that it may not raise sufficient capital, which matters for shareholders.

Key points

  • Net loss attributable to common stockholders was $4.2 million, or $2.94 per share, for Q2 2026, versus $5.7 million, or $31.75 per share, in Q2 2025.
  • General and administrative expenses were $1.6 million, down from $3.1 million; research and development expenses were $2.6 million, unchanged year over year.
  • Cash was $4.1 million at June 30, 2026, down from $5.6 million at December 31, 2025.
  • The FDA gave positive pre-IND feedback on CLD-401, and the company targets first patient dosing in Q1 2027.

The filing

CompanyCalidi Biotherapeutics, Inc. (CLDI)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:45 PM ET
Accession number0001493152-26-037840

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.